Cancer cell therapies exist today, but it is in a form that is inefficient, expensive and unreliable - it needs to be individualised to each patient and can cost up to $500K.
ALA's technology aims to produce an ‘off-the-shelf’ treatment that can be produced using healthy, non-patient specific engineered cells, which if successful, will have significant commercial value.
General updates from ALA
Anagrelide patent for the United States [05-Apr-2022]
ALA: Appointment of medtech veteran as Chairman [14-Mar-2023]
Arovella to present on tomorrow (4/04/2023) [03-Apr-2023]